Evidence map›Paper›PMID 37328812›Full record

SynthesisBMC cancer2023

Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis.

Zahra Maleki, Mohebat Vali, Hossein-Ali Nikbakht, Soheil Hassanipour, Aida Kouhi, Saman Sedighi, Roya Farokhi, Haleh Ghaem

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Integrating network pharmacology and Mendelian randomization to explore potential targets of matrine against ovarian cancer.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zahra Maleki *Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohebat Vali *Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0000-0002-8556-431X
Hossein-Ali NikbakhtSocial Determinants of Health Research Center, Health Research Institute, Department of Biostatistics & Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran.
Soheil HassanipourGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.ORCID http://orcid.org/0000-0001-5848-1116
Aida KouhiDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-6568-5974
Saman SedighiDepartment of Neurosurgery, Keck school of Medicine, University of Southern California, Los Angeles, CA, USA.
Roya FarokhiDepartment of Health, Health Systems Research, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.ORCID http://orcid.org/0000-0001-5942-5490
Haleh GhaemNon-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ghaemh@sums.ac.ir.

Funding

Shiraz University of Medical Sciences 1400-9-9-22591
6 · The paper itself

Abstract

backgroundOvarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequently leads to late diagnosis. Survival rate of patients diagnosed with ovarian cancer can be used in order to better assess current standard of care; the aim of this study is to evaluate the survival rate of ovarian cancer patients in Asia.

methodsSystematic review was performed on articles that were published by the end of August 2021 in five international databases, including Medline / PubMed, ProQuest, Scopus, Web of Knowledge, and Google Scholar. The Newcastle-Ottawa quality evaluation form was used for cohort studies to evaluate the quality of the articles. The Cochran-Q and I

resultsA total of 667 articles were reviewed, from which 108 were included in this study because they passed the criteria. Based on a randomized model, the survival rates of ovarian cancer after 1, 3 and 5 years were respectively 73.65% (95% CI, 68.66-78.64), 61.31% (95% CI, 55.39-67.23) and 59.60% (95% CI, 56.06-63.13). Additionally, based on meta-regression analysis, there was no relationship between the year of study and survival rate.

conclusionsThe 1-year survival rate was higher than that of 3- and 5-year for ovarian cancer. This study provides invaluable information that can not only help establish better standard of care for treatment of ovarian cancer, but also assist in development of superior health interventions for prevention and treatment of the disease.

Indexed as

Ovarian NeoplasmsAsiaFemaleHumansSurvival Rate

Identifiers

PMID37328812
PMCPMC10276364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.